Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · Real-Time Price · USD

1.670

-0.040 (-2.34%)

Sep 5, 2025, 4:00 PM - Market closed

Inhibikase Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2020
Period Ending	Sep '25 Sep 5, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2020
Market Capitalization	124	218	8	13	37	69	Upgrade
Market Cap Growth	1560.26%	2684.93%	-37.83%	-65.89%	-46.68%	-	Upgrade
Enterprise Value	37	215	-9	-14	-8	70	Upgrade
Last Close Price	1.67	3.25	1.27	3.00	8.82	41.40	Upgrade
PS Ratio	-	-	30.10	102.18	11.93	99.29	Upgrade
PB Ratio	1.55	2.30	0.71	0.60	0.96	7.09	Upgrade
P/TBV Ratio	1.55	2.30	0.71	0.60	0.96	7.09	Upgrade
EV/Sales Ratio	-	-	-	-	-	100.29	Upgrade
Debt / Equity Ratio	0	0.00	0.06	0.02	0.01	0.03	Upgrade
Asset Turnover	-	-	0.01	0.00	0.11	0.09	Upgrade
Quick Ratio	9.96	26.13	3.85	6.25	10.08	2.96	Upgrade
Current Ratio	10.09	26.37	4.13	6.60	10.48	3.13	Upgrade
Return on Equity (ROE)	-97.49%	-52.00%	-118.88%	-60.74%	-61.35%	-107.58%	Upgrade
Return on Assets (ROA)	-56.55%	-31.60%	-63.67%	-33.62%	-32.24%	-23.77%	Upgrade
Return on Capital (ROIC)	-64.57%	-33.53%	-76.13%	-37.74%	-37.85%	-58.85%	Upgrade
Earnings Yield	-33.35%	-12.60%	-242.67%	-143.13%	-39.99%	-4.11%	Upgrade
FCF Yield	-16.01%	-8.77%	-230.82%	-139.49%	-38.66%	-1.63%	Upgrade
Buyback Yield / Dilution	-893.41%	-293.35%	-42.74%	-39.15%	-121.72%	-0.39%	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q